# A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea

> **NCT04546828** · PHASE2 · WITHDRAWN · sponsor: **Samsung Medical Center**

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Gemcitabine, Cisplatin, and Nab-Paclitaxe

## Key facts

- **NCT ID:** NCT04546828
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-01
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-08-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** problem of sponsor
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04546828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04546828, "A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04546828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*